
|Slideshows|May 31, 2018
New FDA Warning
Author(s)James Phelps, MD
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.
Advertisement
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach
2
sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation
3
FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder
4
Deciding How to Try to Make This a Better World
5














